DBV Technologies présente de nouvelles données positives issues de l’étude de phase 3 VITESSE, et un aperçu de l’étude THRIVE récemment initiée à l’occasion du Congrès de l’EAACI 2026

DBV Technologies announced positive results from its Phase 3 VITESSE study showing that the VIASKIN® Peanut patch demonstrated statistically significant efficacy versus placebo in peanut-allergic children aged 4-7 years with concurrent atopic conditions including asthma, food allergies, and atopic dermatitis. The company also presented the design of its Phase 2 THRIVE study evaluating the patch in infants aged 6-12 months with peanut allergy, aiming to enable unrestricted peanut consumption after three years of treatment.